Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development

Following significant strides made in advancing its late-stage pipeline with dual positive readouts in 2023 and a few more anticipated this year, Oculis further expands its executive leadership team with the appointment of industry veteran as President of Research & DevelopmentDr. Shah’s joins Oculis from Iveric Bio with extensive experience in drug development, regulatory affairs and ophthalmology, with over a dozen successful market approvals, which will be key as Oculis initiates preparations

Related Keywords

Boston ,Massachusetts ,United States ,Switzerland ,France ,Sylvia Cheung ,Corey Davis ,Snehal Shah ,Roche Genentech ,Iveric Bio ,Drug Administration ,Research Development ,Oculis Holding Ag Nasdaq ,Noven Pharmaceuticals Member Of The Hisamitsu Group ,New Drug Application ,Chief Regulatory ,Product Strategy Officer ,Geographic Atrophy ,Hoffmann La Roche ,Noven Pharmaceuticals ,Hisamitsu Group ,Kyowa Kirin ,Chief Executive Officer ,Eye Diseases ,Mr Shah ,Uculis ,Iopharmaceutical Company ,Development ,Regulatory Experience ,